Skip to main content
SpringerLink
Log in

Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis; insights from CD36-deficient patients

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Oxidized low density lipoprotein (LDL) (Ox-LDL) plays an important role in the pathogenesis of atherosclerosis. Oxidized LDL is taken up by macrophages via scavenger receptors. CD36 is an 88 kDa glycoprotein expressed on platelets, monocyte-macrophages, microvascular endothelial cells, adipose tissue, skeletal muscles and heart. We found patients with CD36 deficiency and identified several mutations in the CD36 gene. We also reported that CD36-deficient macrophages showed a 50% reduction in the binding of Ox-LDL, suggesting that CD36 is one of the major receptors for Ox-LDL. CD36 was expressed on macrophages in the atherosclerotic lesions of human aorta and coronary arteries especially on foamed macrophages. The distribution of CD36 expression was slightly different from that of scavenger receptor class A types I and II. The expression of CD36 on macrophages was up-regulated by Ox-LDL and down-regulated by interferon γ. Since CD36 is a transporter of long-chain fatty acids (LCFA), CD36-deficient patients showed a defect in the uptake of an LCFA analog, BMIPP, by the heart. Furthermore, the secretion of IL-1β and TNF-α from monocyte-derived macrophages induced by Ox-LDL was markedly reduced and the activation of NF-κB was attenuated in CD36-deficient subjects compared with controls, suggesting that CD36-mediated signaling is also impaired in CD36 deficiency.

To elucidate the roles of CD36 in vivo, we characterized the clinical profile of CD36-deficient patients. Most of them were accompanied by hyperlipidemia (mainly hypertriglyceridemia), increased remnant lipoproteins and mild elevation of fasting plasma glucose level and blood pressure. Glucose clamp technique revealed mean whole body glucose uptake was reduced in CD36-deficient patients, indicating the presence of insulin resistance. The frequency of CD36 deficiency was higher in patients with coronary heart disease (CHD) than in control subjects. Taken together, CD36 deficiency is accompanied by (1) hyperlipidemia and increased remnant lipoproteins, (2) impaired glucose metabolism based upon insulin resistance, and (3) mild hypertension, and comprises one of the genetic backgrounds of the metabolic syndrome, leading to the development of CHD. (Mol Cell Biochem xxx: 1–4, 2004)

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tandon NN, Lipsky RH, Burgess WH, et al: Protein isolation and characterization of platelet glycoprotein IV (CD36). J Biol Chem 264: 7570–7575, 1989.

    PubMed  CAS  Google Scholar 

  2. Endemann G, Stanton IW, Madden KS, et al: CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 268: 11811–11816, 1993.

    PubMed  CAS  Google Scholar 

  3. Nozaki S, Kashiwagi H, Yamashita S, et al: Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J Clin Invest 96: 1859–1865, 1995.

    PubMed  CAS  Google Scholar 

  4. Nagy L, Tontonoz P, Alvarez JG, et al: Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93: 229–240, 1998.

    Article  PubMed  CAS  Google Scholar 

  5. Nakagawa T, Nozaki S, Nishida M, et al: Oxidized LDL increases and interferon-gamma decreases expression of CD36 in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 18: 1350–1357, 1998.

    PubMed  CAS  Google Scholar 

  6. Nakata A, Nakagawa Y, Nishida M, et al: CD36, a novel receptor for oxidized low-density lipoproteins is highly expressed on lipid-laden macrophages in human atherosclerotic aorta. Arterioscler Thromb Vasc Biol 19: 1333–1139, 1999.

    PubMed  CAS  Google Scholar 

  7. Nakagawa Y, Yamashita S, Nozaki S, et al: Differential expression of CD36 and scavenger receptor class A type I and type II in human coronary arteries. Atherosclerosis 156: 297–305, 2001.

    Article  Google Scholar 

  8. Febbraio M, Hajjar DP, Silverstein RI: CD36, a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation and lipid metabolism. J Clin Invest 108: 785–791, 2001.

    Article  PubMed  CAS  Google Scholar 

  9. Yamamoto N, Ikeda H, Tandon NN, et al: A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka platelet lack detectable GPIV(CD36). Blood 76: 1698–1703, 1990.

    PubMed  CAS  Google Scholar 

  10. Kashiwagi H, Honda S, Tomiyama Y, et al: A novel polymorphism in glycoprotein IV (replacement of proline-90 by serine) predominates in subjects with platelet GPIV deficiency. Thromb Haemost 69: 481–484, 1993.

    PubMed  CAS  Google Scholar 

  11. Kashiwagi H, Tomiyama Y, Nozaki S, et al: Analyses of genetic abnormalities in type I CD36 deficiency in Japan: identification and cell biological characterization of two novel mutations that cause CD36 deficiency in man. Hum Genet 108: 459–466, 2001.

    Article  PubMed  CAS  Google Scholar 

  12. Janabi MY, Yamashita S, Hirano K, et al: Reduced adhesion of monocyte-derived macrophages from CD36-deficient patients to type I collagen. Biochem Biophys Res Commun 283: 26–30, 2001.

    Article  PubMed  CAS  Google Scholar 

  13. Janabi M, Yamashita S, Hirano K, et al: Oxidized low density lipoprotein-induced activation of NF-κB and subsequent expression of a variety of proinflammatory and proatherogenic genes are defective in monocyte-derived macrophages from CD36-deficient patients. Arterioscler Thromb Vasc Biol 20: 1953–1960, 2000.

    PubMed  CAS  Google Scholar 

  14. Abumrad NA, el-Maghrabi MR, Amri EZ, et al: Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J Biol Chem 268: 17665–17668, 1993.

    CAS  Google Scholar 

  15. Nozaki S, Tanaka T, Yamashita S, et al: CD36 mediates long-chain fatty acid transport in human myocardium: complete myocardial accumulation defect of radiolabeled long-chain fatty acid analog in subjects with CD36 deficiency. Mol Cell Biochem 192: 129–135, 1999.

    Article  PubMed  CAS  Google Scholar 

  16. Tanaka T, Sohmiya K, Kawamura K: Is CD36 deficiency an etiology of hereditary hypertrophic cardiomyopathy? J Mol Cell Cardiol 29: 121–127, 1997.

    Article  PubMed  CAS  Google Scholar 

  17. Tanaka T, Nakata T, Oka T, et al: Defect in human myocardial long-chain fatty acid uptake is caused by FAT/CD36 mutation. J Lipid Res 42: 751–759, 2001.

    PubMed  CAS  Google Scholar 

  18. Miyaoka K, Kuwasako T, Hirano K, et al: CD36 deficiency is associated with insulin resistance. Lancet 357: 686–687, 2001.

    Article  PubMed  CAS  Google Scholar 

  19. Yanai H, Chiba H, Morimoto M, et al: Human CD36 deficiency is associated with elevation in low-density lipoprotein-cholesterol. Am J Med Genet 93: 299–304, 2000.

    Article  PubMed  CAS  Google Scholar 

  20. Yanai H, Chiba H, Fujiwara H, et al: Metabolic changes in human CD36 deficiency displayed by glucose loading. Thromb Haemost 86: 995–999, 2001.

    PubMed  CAS  Google Scholar 

  21. Kuwasako T, Hirano K, Sakai N, Ishigami M, Hiraoka H, Yakub MJ, Yamauchi-Takihara K, Yamashita S, Matsuzawa Y: Lipoprotein abnormalities in human genetic CD36 deficiency associated with insulin resistance and abnormal fatty acid metabolism. Diabetes Care 26: 1647–1648, 2003.

    Article  PubMed  Google Scholar 

  22. Yoshizumi T, Nozaki S, Fukuchi K, et al: Pharmacokinetics and metabolism of 123I-BMIPP fatty acid analog in healthy and CD36-deficient subjects. J Nucl Med 41: 1134–1138, 2000.

    PubMed  CAS  Google Scholar 

  23. Matsumoto K, Hirano K, Nozaki S, et al: Expression of macrophage scavenger receptor, CD36 in cultured human aortic smooth muscle cells, in association with the expression of peroxisome proliferators activated receptor-γ. Arterioscler Thromb Vasc Biol 20: l027–l032, 2000.

    Google Scholar 

  24. Aitman TJ, Glazier AM, Wallace CA, et al: Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 21: 76–83, 1999.

    Article  PubMed  CAS  Google Scholar 

  25. Hajri T, Han XX, Bonen A, et al: Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J Clin Invest 109: 1381–1389, 2002.

    Article  PubMed  CAS  Google Scholar 

  26. Glazier AM, Scott J, Aitman TJ: Molecular basis of the CD36 chromosomal deletion underlying SHR defects in insulin action and fatty acid metabolism. Mamm Genome 13: 108–113, 2002.

    Article  PubMed  CAS  Google Scholar 

  27. Pravenec M, Landa V, Zidek V, et al: Transgenic rescue of defective CD36 ameliorates insulin resistance in spontaneously hypertensive rats. Nat Genet 27: 156–158, 2001.

    Article  PubMed  CAS  Google Scholar 

  28. Hajri T, Ibrahimi A, Coburn CT, et al: Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. J Biol Chem 276: 23661–23666, 2001.

    Article  PubMed  CAS  Google Scholar 

  29. Febbraio M, Abumrad NA, Hajjar DP, et al: A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem 274: 19055–19062, 1999.

    Article  PubMed  CAS  Google Scholar 

  30. Gotoda T, Iizuka Y, Kato N, et al: Absence of CD36 mutation in the original spontaneously hypertensive rats with insulin resistance. Nat Genet 22: 226–228, 1999.

    Article  PubMed  CAS  Google Scholar 

  31. Febbraio M, Podrez EA, Smith JD, et al: Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 105: 1049–1056, 2000.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Molecular Science, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

    Shizuya Yamashita, Ken-Ichi Hirano, Takahiro Kuwasako, Mohamed Janabi, Yumiko Toyama, Masato Ishigami & Naohiko Sakai

  2. Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

    Shizuya Yamashita

Authors
  1. Shizuya Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ken-Ichi Hirano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takahiro Kuwasako
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohamed Janabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yumiko Toyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masato Ishigami
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naohiko Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shizuya Yamashita.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamashita, S., Hirano, KI., Kuwasako, T. et al. Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis; insights from CD36-deficient patients. Mol Cell Biochem 299, 19–22 (2007). https://doi.org/10.1007/s11010-005-9031-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-005-9031-4

Key words

Search

Navigation